LIBRE LIFE LATEST NEWS

Dexcom users were furious after being confronted with app Ts&Cs demanding agreement before they could access glucose readings. The backlash over AI, personal data and legal rights has also exposed frustration over sensor accuracy and reliability. What does it mean for UK T1Ds?

British startup Sava Technologies is developing a new CGM using microsensors ten times shorter than conventional sensor filaments. Backed by $36 million in funding and a partnership with Ascensia, could it become a serious alternative to FreeStyle Libre and Dexcom?

Diabetes UK received £43.8 million in 2025, but only 6½p in every £1 was committed to new research from its core funds. We look at where the rest goes, who sets the priorities, how much influence ordinary fundraisers really have, and why major funders can negotiate very different terms.

Novo Nordisk is adopting the shorter name ‘Novo’ as part of a major global rebrand. Behind the new logo is a wider shift in how one of diabetes’s oldest companies sees healthcare, patients and an increasingly consumer-driven market.

New research analysing almost 47 million CGM readings reveals how often glucose reaches a sensor's measurement limits, how long it can remain there and what that means for the information we see.